Adoptive cell therapy is a type of immunotherapy that utilizes either natural killer (NK) cells or T cells to treat cancer and certain infections. NK cells and T cells are derived from lymphocytes that play a major role in the body’s immune response. Adoptive cell therapy mainly involves collecting immune cells from a patient’s or donor’s blood and modifying them in the laboratory to increase their ability to fight cancer cells. The modified cells are then infused back into the patient to trigger an immune response against cancerous cells. Adoptive cell therapy is an effective and promising cancer treatment approach with much stronger and longer-lasting benefits compared to chemotherapy. It allows for individualized treatment based on a patient’s unique cancer.
The global Adoptive Cell Therapy Market is estimated to be valued at US$ 6903.93 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the adoptive cell therapy market is growing research on CAR T-cell therapy for solid tumors. While CAR T-cell therapy has shown great promise in the treatment of hematological cancers, its effectiveness in solid tumors still needs to be improved. Researchers are exploring various approaches such as co-introducing PD-1/PD-L1 blockade, cytokine support, and utilizing dual-targeting CAR T cells to make solid tumors more responsive to CAR T-cell therapy. Enhanced T-cell potency, T-cell trafficking ability, and overcoming tumor immunosuppression are also areas of focus. Advancements in these areas could expand the applications of CAR T-cell therapy to various solid tumor types in the coming years. Another notable trend is increasing collaborations between biotech companies and research institutes for developing off-the-shelf allogeneic CAR T-cell therapies. These “ready-to-use” treatments do not require genetically modifying a patient’s own T cells, simplifying the manufacturing process to achieve economies of scale. It also avoids limitations related to a patient’s health condition or inability to manufacture autologous CAR T cells.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is low for adoptive cell therapy market due to high capital requirements and stringent regulations.
Bargaining power of buyers: The bargaining power of buyers is moderate as the demand for adoptive cell therapy is increasing but there are only a few players operating in this market.
Bargaining power of suppliers: The bargaining power of suppliers is low due to the presence of multiple raw material suppliers.
Threat of new substitutes: There is no significant threat from substitutes as there are limited treatment alternatives for cancer.
Competitive rivalry: The competition in adoptive cell therapy market is high due to presence of large players.
Key Takeaways
The Global Adoptive Cell Therapy Market Size is expected to witness high growth. Rising cancer incidence and growing R&D activities are fueling the market growth. The global Adoptive Cell Therapy Market is estimated to be valued at US$ 6903.93 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
North America dominates the adoptive cell therapy market owing to increasing funding for cancer research and growing adoption of immunotherapy in the region. Europe adoptive cell therapy market is also expected to grow at a significant rate during the forecast period. This is attributed to rising healthcare funding coupled with growing prevalence of cancer. The Asia Pacific adoptive cell therapy market is projected to grow at the fastest pace over the next few years due to rising awareness levels and improving healthcare facilities in emerging countries such as China and India.
Key players
Key players operating in the adoptive cell therapy market are Broadcom, Celeno Communications, Infineon Technologies, Espressif Systems Shanghai Co Ltd. Growing partnerships and acquisitions are helping these players to strengthen their product portfolio and international presence. Broadcom recently acquired a graphics company to enhance its artificial intelligence capabilities.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it